US FDA Gets Earful On Biologic ‘Umbrella’ Exclusivity, Patent Listings, Biosimilar Bridging Study Waivers
Executive Summary
BIO and PhRMA want an exclusivity policy that protects subsequent changes to innovator biologics and oppose patent listings in the Purple Book; AAM says agency should waive unnecessary clinical bridging studies based on information provided under confidentiality agreements with foreign regulators.
You may also be interested in...
Gottlieb's Greatest Strength As US FDA Commissioner? Stability
Amid all the praise for his raising of FDA's profile and aggressive policy stances, Scott Gottlieb's most valuable contribution while in office may have been leaving the agency fundamentally unchanged, an important lesson for incoming Acting Commissioner Norman Sharpless.
BsUFA III: Industry Eyes Streamlined Review Of New Indications, Phased Review Process
Janssen and Amgen suggest user fee agreement changes aimed at speeding review process for some biosimilar applications and supplements in comments to US FDA on biologic product competition and innovation, while Merck presses agency to clarify its current view on cross-product labeling.
BsUFA III: Industry Eyes Streamlined Review Of New Indications, Phased Review Process
Janssen and Amgen suggest user fee agreement changes aimed at speeding review process for some biosimilar applications and supplements in comments to US FDA on biologic product competition and innovation, while Merck presses agency to clarify its current view on cross-product labeling.